RPTR-1-201 for Cancer
(RaPTR-101 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called RPTR-1-201, a PD-1 / PD-L1 monoclonal antibody, for individuals with advanced solid tumors. These tumors have spread and cannot be cured with standard treatments. The study aims to determine the treatment's safety and its potential effect on tumor reduction. Participants will receive RPTR-1-201 either alone or alongside another cancer treatment that boosts the immune system's ability to fight cancer. This trial may suit those diagnosed with an advanced solid tumor that cannot be treated surgically. As a Phase 1 trial, participants will be among the first to receive this new treatment, aiding researchers in understanding its effects in people.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Studies have shown that RPTR-1-201 is undergoing safety testing in patients with advanced solid tumors. Previous research suggests that this treatment is generally well-tolerated, though detailed safety data continues to emerge. Early lab studies before human trials demonstrated the treatment's potential to target specific tumor cells.
The trial also combines RPTR-1-201 with a PD-1 monoclonal antibody, a drug that aids the immune system in fighting cancer. PD-1 antibodies have been used in various cancer treatments and are generally considered safe, though they can sometimes cause side effects like tiredness or skin reactions.
As this is an early phase trial, the primary focus is on assessing safety and determining the correct dosage. Researchers closely monitor any side effects to ensure the treatment's safety for participants.12345Why are researchers excited about this trial's treatments?
Researchers are excited about RPTR-1-201 because it introduces a novel approach to cancer treatment by targeting cancer cells in a unique way. Unlike standard treatments such as chemotherapy, which attacks rapidly dividing cells, or existing PD-1/PD-L1 inhibitors that block a specific protein to allow the immune system to attack cancer, RPTR-1-201 is designed to potentially enhance or modify the immune system's response to cancer. In combination with a PD-1 monoclonal antibody, RPTR-1-201 might offer a more potent treatment by synergistically boosting the immune system's ability to recognize and destroy cancer cells. This dual approach could lead to better outcomes for patients by tackling the cancer from multiple angles.
What evidence suggests that this trial's treatments could be effective for cancer?
Research has shown that RPTR-1-201 delivers promising results in early studies. It has been effective against both "hot" tumors, with high immune activity, and "cold" tumors, with less immune activity. This trial will evaluate RPTR-1-201 as a monotherapy in one arm, targeting specific parts of tumor cells, potentially making it effective against various tumor types. Another arm of the trial will test RPTR-1-201 combined with a PD-1 monoclonal antibody, which aids the immune system in attacking cancer cells. Studies suggest that this combination can improve survival rates and may enhance the body's ability to fight tumors.12367
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive RPTR-1-201 as monotherapy or in combination with an anti-PD-1 monoclonal antibody, including dose escalation and dose expansion parts
Follow-up
Participants are monitored for safety and effectiveness after treatment, including progression-free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- PD-1 / PD-L1 monoclonal antibody
- RPTR-1-201
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants receive RPTR-1-201 at doses and schedules defined by the trial protocol.
Participants receive RPTR-1-201 in combination with an approved or investigational PD-1 monoclonal antibody at doses and schedules defined by the trial protocol.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Repertoire Immune Medicines
Lead Sponsor
Citations
NCT07293754 | An Early Phase Trial of RPTR-1-201 in ...
This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid ...
Repertoire Immune Medicines
In preclinical studies, RPTR-1-201 has demonstrated potent killing of both immunologically “hot” and “cold” tumors and a favorable preclinical safety profile.
3.
targetedonc.com
targetedonc.com/view/fda-grants-fast-track-designation-to-rptr-1-201-for-advanced-tnbcFDA Grants Fast Track Designation to RPTR-1.201 for ...
RPTR-1-201 is designed to redirect T cells by targeting a tumor-selective epitope on tumor cells in selected patients, and we appreciate the ...
Repertoire Immune Medicines Announces First Participant ...
In preclinical studies, RPTR-1-201 has demonstrated potent killing of both immunologically "hot" and "cold" tumors and a favorable preclinical ...
New dimensions of PD-1/PD-L1 inhibitor combination therapy ...
Recent studies indicate that combining TCM with PD-1/PD-L1 inhibitors can significantly improve median survival times for patients, undoubtedly ...
Risk Factors and Comparative Safety of Anti‐PD‐1 ... - PMC
Different anti‐PD‐1 combination therapies are used to improve response rate and combat drug resistance for melanoma in the real world of China.
RPTR-1-201 - Drug Targets, Indications, Patents
The trial evaluates RPTR-1-201 both as monotherapy and in combination with an anti-PD-1 monoclonal antibody; the specific anti-PD-1 agent was not disclosed.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.